Neutral Rating for AbbVie Amid Revenue Challenges and Limited Upside Potential
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...
FiercePharma14d
JPM25, Day 3: AbbVie's 'clear runway to growth' allows it to focus on early-stage acquisitions
Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...
Nasdaq26d
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...
Quotidianosanità.it26d
Epatite C. Nuovi farmaci “interferon free” solo per pochi. Aifa fissa i criteri per l’accesso. Ecco chi potrà accedervi e a chi rivolgersi
Tale accesso per uso nominale è aperto a tutti i pazienti, per le cui richieste di trattamento i centri non inclusi nella lista allegata potranno contattare la Direzione Medica di AbbVie srl”.
Quotidianosanità.it27d
Epatite C. Aifa: “Per Viekirax/Exviera raggiunto primo scaglione trattamenti. Applicato meccanismo prezzo/volume”
“in applicazione dei termini dell'accordo confidenziale sottoscritto ad esito della negoziazione del prezzo e della rimborsabilità dei medicinali Viekirax e Exviera con la ditta Abbvie Srl, è ...
Nasdaq28d
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
AbbVie (ABBV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...